ARS Pharmaceuticals (SPRY) Total Liabilities (2020 - 2026)

ARS Pharmaceuticals has disclosed Total Liabilities across 7 years of filings, most recently posting $226.3 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $226.3 million, up 130.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $226.3 million (up 130.07% YoY), and the FY2025 annual result was $213.4 million, up 126.16% from the prior year.
• Total Liabilities came in at $226.3 million for Q1 2026 at ARS Pharmaceuticals, up from $213.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $226.3 million in Q1 2026 to a low of $2.4 million in Q4 2023.
• The 5-year median for Total Liabilities is $15.2 million (2022), against an average of $63.9 million.
• Across the five-year window, Total Liabilities plunged 80.47% in 2022 and jumped 3786.12% in 2024, its largest moves.
• ARS Pharmaceuticals' Total Liabilities stood at $8.5 million in 2022, then tumbled by 71.6% to $2.4 million in 2023, then surged by 3786.12% to $94.4 million in 2024, then jumped by 126.16% to $213.4 million in 2025, then grew by 6.03% to $226.3 million in 2026.
• The last three Total Liabilities figures came in at $226.3 million (Q1 2026), $213.4 million (Q4 2025), and $225.1 million (Q3 2025), per Business Quant data.